ACTR087 (Cogent Biosciences)

**ACTR087** is an investigational autologous engineered T-cell therapy developed by Unum Therapeutics, subsequently renamed Cogent Biosciences. Patient-derived T cells are transduced ex vivo to express an Antibody-Coupled T-cell Receptor comprising a CD16V158 extracellular Fc-binding domain linked to 4-1BB and CD3ζ signaling domains. The engineered cells bind the Fc region of a co-administered tumor-targeting IgG antibody, allowing the antibody to determine tumor-antigen specificity and triggering T-cell activation and cytotoxicity. ACTR087 was evaluated in Phase 1 studies with rituximab for relapsed or refractory CD20-positive B-cell lymphomas and with SEA-BCMA for relapsed or refractory multiple myeloma. The lymphoma program was deprioritized after safety-related regulatory events, and the multiple-myeloma study was terminated. ([ashpublications.org](https://ashpublications.org/blood/article/134/Supplement_1/244/426238/A-Phase-1-Study-of-ACTR087-in-Combination-with))

Other names

ACTR+ T cellsACTR T cellsAntibody-Coupled T-cell Receptor T cellsautologous ACTR T cellsAutologous T lymphocytes expressing Antibody-Coupled T-cell Receptors